Literature DB >> 12759283

Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs.

J Martel-Pelletier1, D Lajeunesse, P Reboul, J-P Pelletier.   

Abstract

Dual 5-LOX/COX inhibitors are potential new drugs to treat inflammation. They act by blocking the formation of both prostaglandins and leucotrienes but do not affect lipoxin formation. Such combined inhibition avoids some of the disadvantages of selective COX-2 inhibitors and spares the gatrointestinal mucosa.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12759283      PMCID： PMC1754580          DOI： 10.1136/ard.62.6.501

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  90 in total

Review 1.  Cyclooxygenase 2 and the kidney.

Authors:  M D Breyer; R C Harris
Journal:  Curr Opin Nephrol Hypertens       Date:  2001-01       Impact factor: 2.894

Review 2.  Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways.

Authors:  C N Serhan; E Oliw
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

3.  Contribution of cyclooxygenase 2 to liver regeneration after partial hepatectomy.

Authors:  M Casado; N A Callejas; J Rodrigo; X Zhao; S K Dey; L Boscá; P Martín-Sanz
Journal:  FASEB J       Date:  2001-07-09       Impact factor: 5.191

Review 4.  The coxibs, selective inhibitors of cyclooxygenase-2.

Authors:  G A FitzGerald; C Patrono
Journal:  N Engl J Med       Date:  2001-08-09       Impact factor: 91.245

Review 5.  Neutrophils, endothelial cells, and cysteinyl leukotrienes: a new approach to neutrophil-dependent inflammation?

Authors:  A Sala; G Folco
Journal:  Biochem Biophys Res Commun       Date:  2001-05-25       Impact factor: 3.575

Review 6.  Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors.

Authors:  M Katori; M Majima
Journal:  Inflamm Res       Date:  2000-08       Impact factor: 4.575

Review 7.  COX-2 and the kidneys.

Authors:  D O Stichtenoth; J C Frölich
Journal:  Curr Pharm Des       Date:  2000-11       Impact factor: 3.116

Review 8.  Cyclo-oxygenase products and atherothrombosis.

Authors:  G A FitzGerald; S Austin; K Egan; Y Cheng; D Pratico
Journal:  Ann Med       Date:  2000-12       Impact factor: 4.709

9.  Dual inhibition of 5-lipoxygenase and cyclooxygenases 1 and 2 by ML3000 reduces joint destruction in adjuvant arthritis.

Authors:  R E Gay; M Neidhart; F Pataky; S Tries; S Laufer; S Gay
Journal:  J Rheumatol       Date:  2001-09       Impact factor: 4.666

10.  Lipid mediator class switching during acute inflammation: signals in resolution.

Authors:  B D Levy; C B Clish; B Schmidt; K Gronert; C N Serhan
Journal:  Nat Immunol       Date:  2001-07       Impact factor: 25.606
View more
  79 in total

1.  Anti-inflammatory effect of acetylpuerarin on eicosanoid signaling pathway in primary rat astrocytes.

Authors:  Yanxiao Xiang; Xinbing Wei; Lin Chen; Huiqing Liu; Xiaoqian Liu; Tian Wang; Xiumei Zhang
Journal:  J Mol Neurosci       Date:  2013-09-13       Impact factor: 3.444

Review 2.  Current approaches to prevent NSAID-induced gastropathy--COX selectivity and beyond.

Authors:  Jan C Becker; Wolfram Domschke; Thorsten Pohle
Journal:  Br J Clin Pharmacol       Date:  2004-12       Impact factor: 4.335

Review 3.  Pharmacodynamic mechanisms of anti-inflammatory drugs on the chemosensitization of multidrug-resistant cancers and the pharmacogenetics effectiveness.

Authors:  Neda Gholamian Dehkordi; Seyed Abbas Mirzaei; Fatemeh Elahian
Journal:  Inflammopharmacology       Date:  2020-10-17       Impact factor: 4.473

4.  Docosahexaenoic acid differentially affects TNFα and IL-6 expression in LPS-stimulated RAW 264.7 murine macrophages.

Authors:  Kaori L Honda; Stefania Lamon-Fava; Nirupa R Matthan; Dayong Wu; Alice H Lichtenstein
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2015-04-11       Impact factor: 4.006

5.  Nitroxide derivatives of non-steroidal anti-inflammatory drugs exert anti-inflammatory and superoxide dismutase scavenging properties in A459 cells.

Authors:  Wilmarie Flores-Santana; Terry Moody; Weibin Chen; Michael J Gorczynski; Mai E Shoman; Carlos Velázquez; Angela Thetford; James B Mitchell; Murali K Cherukuri; S Bruce King; David A Wink
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 6.  Licofelone: the answer to unmet needs in osteoarthritis therapy?

Authors:  Shrinivas K Kulkarni; Vijay P Singh
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

7.  Regulation of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase-activating protein/5-lipoxygenase by 4-hydroxynonenal in human osteoarthritic chondrocytes.

Authors:  Shu-Huang Chen; Hassan Fahmi; Qin Shi; Mohamed Benderdour
Journal:  Arthritis Res Ther       Date:  2010-02-09       Impact factor: 5.156

8.  Targeted deep resequencing of ALOX5 and ALOX5AP in patients with diabetes and association of rare variants with leukotriene pathways.

Authors:  Marek Postula; Piotr Kazimierz Janicki; Marek Rosiak; Ceren Eyileten; Małgorzata Zaremba; Agnieszka Kaplon-Cieslicka; Shigekazu Sugino; Dariusz Artur Kosior; Grzegorz Opolski; Krzysztof Jerzy Filipiak; Dagmara Mirowska-Guzel
Journal:  Exp Ther Med       Date:  2016-05-11       Impact factor: 2.447

9.  Discovery of a novel activator of 5-lipoxygenase from an anacardic acid derived compound collection.

Authors:  Rosalina Wisastra; Petra A M Kok; Nikolaos Eleftheriadis; Matthew P Baumgartner; Carlos J Camacho; Hidde J Haisma; Frank J Dekker
Journal:  Bioorg Med Chem       Date:  2013-10-23       Impact factor: 3.641

Review 10.  Activity and potential role of licofelone in the management of osteoarthritis.

Authors:  Arrigo F G Cicero; Luca Laghi
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.